Inventor
HOVEYDA HAMID
BE23 patents
⚠️ This page may combine multiple inventors who share the name “HOVEYDA HAMID”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
OGEDA SA
11 patentsUS10836768B2Nov 17, 2020
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA1 citations72
US10787458B2Sep 29, 2020
Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines
OGEDA SA2 citations72
US10183948B2Jan 22, 2019
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA1 citations72
US9987274B2Jun 5, 2018
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
OGEDA SA4 citations72
US9969745B2May 15, 2018
N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
OGEDA SA2 citations72
US11478472B2Oct 25, 2022
NK-3 receptor antagonists for therapeutic treatment of leptin-related disease
OGEDA SA1 citations71
US10624890B2Apr 21, 2020
NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
OGEDA SA2 citations71
US12162849B2Dec 10, 2024
Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-d3 deuterated form thereof
OGEDA SA0 citations62
US11078203B2Aug 3, 2021
Deuterated fezolinetant
OGEDA SA1 citations62
US12458641B2Nov 4, 2025
NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
OGEDA SA0 citations61
US10214533B2Feb 26, 2019
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
OGEDA SA0 citations51
EUROSCREEN SA
5 patentsUS9422299B2Aug 23, 2016
Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
EUROSCREEN SA17 citations91
US9969738B2May 15, 2018
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
EUROSCREEN SA2 citations72
US10030025B2Jul 24, 2018
Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
EUROSCREEN SA1 citations51
US9840508B2Dec 12, 2017
N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
EUROSCREEN SA0 citations51
US9770435B2Sep 26, 2017
Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EUROSCREEN SA0 citations38
OCERA THERAPEUTICS INC
3 patentsUS10258602B2Apr 16, 2019
Macrocyclic ghrelin receptor modulators and methods of using the same
OCERA THERAPEUTICS INC0 citations51
US10040751B2Aug 7, 2018
Intermediates for macrocyclic compounds
OCERA THERAPEUTICS INC0 citations51
US9949949B2Apr 24, 2018
Macrocyclic ghrelin receptor modulators and methods of using the same
OCERA THERAPEUTICS INC0 citations51